{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036151","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.795403+00:00","generated_at":"2026-06-04T07:52:53.697097+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viking Therapeutics Reports Positive Phase 1 Results for Oral VK2735 with Up to 5.3% Weight Loss","bullets":["Up to 5.3% mean weight loss from baseline after 28 days in Phase 1 MAD trial of oral VK2735","Placebo-adjusted mean weight loss up to 3.3%; up to 57% of treated subjects achieved ≥5% weight loss vs 0% placebo","VK2735 well-tolerated with low GI adverse events; no serious adverse events reported","Company plans Phase 2 trial in obesity for second half of 2024"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036151","json":"https://secwatch.observer/filing/0000950170-24-036151.json","markdown":"https://secwatch.observer/filing/0000950170-24-036151.md","text":"https://secwatch.observer/filing/0000950170-24-036151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024036151/0000950170-24-036151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024036151/vktx-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:52:53.697097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}